Doxifluridine - Aida Pharmaceuticals

Drug Profile

Doxifluridine - Aida Pharmaceuticals

Alternative Names: 5'-deoxy-5-fluorouridine; 5-deoxy-fluorordine

Latest Information Update: 28 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aida Pharmaceuticals
  • Class Antineoplastics; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 28 May 2008 No development reported - Preregistration for Cancer in China (Injection)
  • 30 Jun 2006 Preregistration for Cancer in China (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top